LAUSR

Key Points Question How does the use of tenecteplase compare with the use of alteplase in the clinical outcomes of patients with acute ischemic stroke (AIS) receiving intravenous thrombolysis? Findings In this systematic review and meta-analysis, 6 nonrandomized studies including 1820 participants were analyzed. Intravenous tenecteplase was associated with better short-term and long-term functional outcomes in patients with AIS and a higher likelihood of successful recanalization in patients with acute intracranial vessel occlusions; no increased risk of intracranial bleeding was noted with intravenous tenecteplase compared with alteplase. Meaning Analysis of evidence from nonrandomized studies suggests that tenecteplase is as safe as alteplase for the treatment of AIS and tenecteplase is potentially associated with more favorable outcomes.